Pfizer has shipped 12 million treatment courses of Covid-19 oral drug across 37 countries. Credit: Steve Buissinne from Pixabay.

Pfizer has announced plans to invest $120m in its manufacturing facility in Kalamazoo, Michigan, US, to produce its Covid-19 oral drug, Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets).

The new investment will help in expanding the active pharmaceutical ingredient (API) and registered starting materials (RSMs) production.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

They are used to produce the novel main protease (Mpro) inhibitor, nirmatrelvir.

This expansion will create more than 250 new manufacturing jobs at the Kalamazoo facility.

Pfizer stated that the expansion of API and RSMs production for nirmatrelvir will allow it to increase the Paxlovid supply capacity to meet the worldwide demand.

The company has shipped 12 million Paxlovid courses across 37 countries, including five million shipped to the US, till date.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pfizer chief global supply officer Mike McDermott said: “The Kalamazoo facility uses some of our most innovative manufacturing technology and has been essential in Pfizer’s fight against Covid-19, producing nearly one billion doses of Covid-19 vaccine at the site to date.

“Through this expansion, we will continue to invest in the next generation of manufacturing and supply chain resilience.”

In Kalamazoo, the company is also planning to expand its Modular Aseptic Processing (MAP) sterile injectable pharmaceutical production site.

The latest expansion follows a $450m investment in phase one to build a 400,000ft2 production plant.

In January this year, Pfizer received Health Canada authorisation for its cocktail of two antiviral drugs, nirmatrelvir and ritonavir, to treat adult patients with mild-to-moderate Covid-19.

Paxlovid, the combination therapy, is intended for the treatment of individuals who are at increased risk of disease progression, including hospital admission or death.